Marvel Biosciences Corp. to Commence cGMP Manufacturing of Its Lead Asset MB-204
Calgary, Alberta--(Newsfile Corp. - July 21, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that the Company's wholly owned subsidiary, Marvel Biotechnology Inc., has achieved a significant science milestone in the development of its lead compound MB-204. Marvel Biotechnology Inc. has entered into a current good manufacturing process (cGMP) manufacturing agreement (the "Agreement") with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun") for the...
2021-07-21 8:30 AM EDT
Alphanco Venture Corp. Changes Name to Marvel Biosciences Corp. and Completes Acquisition of Marvel Biotechnology Inc.
Calgary, Alberta--(Newsfile Corp. - July 8, 2021) - Alphanco Venture Corp. (TSXV: AVC.P) (the "Company" or "AVC"), a capital pool company listed on the TSX Venture Exchange (the "TSXV"), is pleased to announce that it has closed its proposed "Qualifying Transaction," as defined under TSXV policies, being the acquisition of all of the outstanding shares (the "Transaction") of Marvel Biotechnology Inc., ("Marvel Biotech") effective June 14, 2021. In connection with closing of the Qualifying...
2021-07-08 1:24 PM EDT